Seoul National University Hospital

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
Lundi, février 26, 2024
NSCLC, Traffic barrier, Severance Hospital, EGFR, ESMO, ASCO, Permeability, Catholic University of Korea, National Cancer Center, Hospital, Asan Medical Center, AACR, Society, University, Seoul National University Hospital, Patient, Clinical trial, Oncology, Mutation, Trial of the century, Cancer, Pharmaceutical industry

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
Lundi, février 26, 2024
NSCLC, Traffic barrier, Severance Hospital, EGFR, ESMO, Multimedia, ASCO, Permeability, Catholic University of Korea, National Cancer Center, Hospital, Asan Medical Center, AACR, Society, University, Seoul National University Hospital, Patient, Clinical trial, Oncology, Mutation, Trial of the century, Cancer, Pharmaceutical industry

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

Sky Labs' CART BP Becomes the World's First to Complete Comparative Studies with All Blood Pressure Measurement Methods

Retrieved on: 
Mercredi, février 14, 2024
Blood pressure, CE, Hospital, Multimedia, US FDA, ABPM, Scientific Reports, KCJ, Seoul National University Hospital, Journal, CART, Research, Medical device

SEOUL, South Korea, Feb. 14, 2024 /PRNewswire/ -- CART BP is a ring-type 24/7 blood pressure monitor of the global healthcare startup Sky Labs(CEO Jack, Lee), and has fully established itself as the only ring-type wearable medical device to complete comparative studies with all blood pressure measurement methods, becoming the first in the world.  

Key Points: 
  • There are currently three main blood pressure measurement methods: auscultatory method in which a cuff-based blood pressure monitor and stethoscope are used in clinics to measure blood pressure; invasive blood pressure measurement method in which a needle or catheter is inserted into an artery (A-line) to measure intra-arterial pressure; and Ambulatory Blood Pressure Monitoring (ABPM) that measures blood pressure during a 24-hour period outside clinics by attaching a cuff and monitor to the body.
  • To prove CART BP's effectiveness, Sky Labs completed all comparative studies with these three blood pressure measurement methods.
  • In addition, Sky Labs validated accuracy in comparative studies with the invasive arterial blood pressure measurement method and standard stethoscopy.
  • CART BP is highly useful compared to other blood pressure monitors in that it enables 24-hour measurements of even blood pressure variability when an individual is asleep, not to mention awake.

Sky Labs' CART BP Becomes the World's First to Complete Comparative Studies with All Blood Pressure Measurement Methods

Retrieved on: 
Mercredi, février 14, 2024
Blood pressure, CE, Hospital, US FDA, ABPM, Scientific Reports, KCJ, Seoul National University Hospital, Journal, CART, Research, Medical device

SEOUL, South Korea, Feb. 14, 2024 /PRNewswire/ -- CART BP is a ring-type 24/7 blood pressure monitor of the global healthcare startup Sky Labs(CEO Jack, Lee), and has fully established itself as the only ring-type wearable medical device to complete comparative studies with all blood pressure measurement methods, becoming the first in the world.  

Key Points: 
  • There are currently three main blood pressure measurement methods: auscultatory method in which a cuff-based blood pressure monitor and stethoscope are used in clinics to measure blood pressure; invasive blood pressure measurement method in which a needle or catheter is inserted into an artery (A-line) to measure intra-arterial pressure; and Ambulatory Blood Pressure Monitoring (ABPM) that measures blood pressure during a 24-hour period outside clinics by attaching a cuff and monitor to the body.
  • To prove CART BP's effectiveness, Sky Labs completed all comparative studies with these three blood pressure measurement methods.
  • In addition, Sky Labs validated accuracy in comparative studies with the invasive arterial blood pressure measurement method and standard stethoscopy.
  • CART BP is highly useful compared to other blood pressure monitors in that it enables 24-hour measurements of even blood pressure variability when an individual is asleep, not to mention awake.

CEPI Partners With Lemonex to Advance mRNA Vaccine Delivery Against Future Pandemic Threats

Retrieved on: 
Lundi, janvier 8, 2024
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, RNA, LNP, Disease, Partnership, Risk, Multimedia, Messenger, South Korea, Vaccine, CEPI, Vaccination, Clinical trial, Infection, Temperature, Seoul National University Hospital, Safety, Policy

CEPI has partnered with Lemonex Inc. (Lemonex), a biotechnology company in the Republic of Korea, to advance their mRNA drug delivery technology, DegradaBALL®, which has the potential to both minimise post-mRNA vaccination side effects and improve access to future mRNA vaccines.

Key Points: 
  • CEPI has partnered with Lemonex Inc. (Lemonex), a biotechnology company in the Republic of Korea, to advance their mRNA drug delivery technology, DegradaBALL®, which has the potential to both minimise post-mRNA vaccination side effects and improve access to future mRNA vaccines.
  • (Photo: Lemonex Inc.)
    CEPI is providing Lemonex up to US $4.6 million in funding to evaluate the safety of the DegradaBALL® mRNA vaccine platform in a Phase I clinical study taking place at Seoul National University Hospital.
  • The funding will also support the development of a freeze-dried formulation to reduce complex-cold chain vaccine storage requirements and increase the use of mRNA vaccines in the Global South.
  • Dr. Richard Hatchett, CEO of CEPI, said: “Clinically validated for the first time during the COVID-19 pandemic, mRNA vaccines will be critical if we are to accelerate our responses to future infectious disease threats.

TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights

Retrieved on: 
Mercredi, octobre 25, 2023
Anatomy, CAD, Plaque, Innovation, Acute coronary syndrome, Trial of the century, Physician, FACC, Coronary artery disease, City centre, ICA, Atherosclerosis, Seoul National University Hospital, CCTA, GE, Risk, Surgeon, ACS, University, GE HealthCare, CABG, TCT, Safety, Patient, Doctor of Philosophy, Prognosis, Cardiovascular disease, Medical device, Medical imaging, Pharmaceutical industry, MD, Cardiology

MOUNTAIN VIEW, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive integrated artificial intelligence (AI) heart care solutions, today announced results from three clinical studies supporting the use of advanced coronary computed tomography angiography (CCTA)-based technologies in the assessment of patients with suspected coronary artery disease (CAD). Results from the ADVANCE-DK Plaque, EMERALD II, and FASTTRACK-CABG studies were presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

Key Points: 
  • Results from the ADVANCE-DK Plaque, EMERALD II, and FASTTRACK-CABG studies were presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
  • The data build on HeartFlow’s extensive body of clinical evidence supporting AI-powered non-invasive diagnostic testing for patients with CAD.
  • Together, this comprehensive solution offers valuable data not currently available with traditional non-invasive diagnostics tools.
  • FASTTRACK-CABG is an investigator-driven study sponsored by the University of Galway, Ireland and co-funded by HeartFlow and GE HealthCare.

Genome Insight Announces Upcoming Presentations at 2023 NORD Breakthrough Summit on Enhancing Diagnostic Precision for Sensorineural Hearing Loss

Retrieved on: 
Lundi, octobre 16, 2023
Science, Biotechnology, Research, Health, Data Management, Hospitals, Technology, Genetics, Seoul National University Hospital, Insight, Huber loss, Trial of the century, Whole genome sequencing, Disease, Sensorineural hearing loss, WGS, Database, Rare, SNHL, Patient, Pharmaceutical industry, Vaccine

Genome Insight is set to unveil clinical research findings on the genetic foundation of rare diseases at the 2023 NORD Rare Disease & Orphan Products Breakthrough Summit (2023 NORD Breakthrough Summit) in Washington, DC.

Key Points: 
  • Genome Insight is set to unveil clinical research findings on the genetic foundation of rare diseases at the 2023 NORD Rare Disease & Orphan Products Breakthrough Summit (2023 NORD Breakthrough Summit) in Washington, DC.
  • Genome Insight will present the results of a collaborative clinical study on Whole Genome Sequencing (WGS) in rare diseases, specifically focusing on sensorineural hearing loss (SNHL).
  • With a WGS pipeline exclusively designed for rare diseases (‘RareVision’), Genome Insight has fostered its collaborations with global medical institutions.
  • "We are thrilled to present our groundbreaking rare disease research at the esteemed 2023 NORD Breakthrough Summit," stated June-Young Koh, M.D./Ph.D.

Pulmuone Launches Gourmet Vending Machines Across South Korea in Partnership with Yo-Kai Express

Retrieved on: 
Mercredi, septembre 27, 2023
CES, Partnership, Tonkotsu ramen, University, Airport, Pulmuone, Seoul Metropolitan Police Agency, Hospital, Seoul National University Hospital, Museum, System, Seoul Metropolitan Subway, Food delivery

FULLERTON, Calif. and SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Pulmuone, the largest tofu company in the world and makers of America's leading tofu brands including Nasoya and Wildwood, today announced the launch of Robot Chef Chulchul Box, a vending machine concept powered by Yo-Kai Express that will offer hot gourmet meals ready in just 90 seconds. Robot Chef Chulchul Box builds on Pulmuone's existing initial success in the unmanned vending machine category within the United States, and will now reach a larger global market by offering South Korean consumers a new way to enjoy high-quality food on the go.

Key Points: 
  • Pulmuone will also be conducting demonstrations and tastings at food expositions throughout South Korea to preview the machines.
  • Yo-Kai Express is also developing a model to create device-specific products and handle direct distribution in South Korea.
  • Pulmuone's tofu brand, Nasoya, teamed up with Yo-Kai Express at CES in 2022 to feature Nasoya's Plantspired® Steak in Yo-Kai Express machines.
  • Expanding its partnership, Pulmuone has now secured exclusive rights to leverage Yo-Kai Express's technology to fuel the launch of Robot Chef Chulchul Box in South Korea, enabling Pulmuone to offer hot food options at vending machines for the first time.

VUNO's First AI-based Prospective Study Results Published in Critical Care

Retrieved on: 
Lundi, septembre 18, 2023
Blood pressure, Real, Dong-a University Hospital, Cardiac arrest, Cohort (statistics), Bed, Respiratory rate, National Early Music Association, MFDS, MEWS, Research, Multimedia, AUROC, RWD, Real World, Thermoregulation, Korean Ministry of Culture, Seoul National University Hospital, Vital signs, Patient, Patient safety, UIT, NEWS, Trial of the century, Heart rate, Medical device, Pharmaceutical industry, Nursing, Critical care, Food

VUNO announced that the multicenter clinical study paper, which confirms the clinical validity of VUNO Med®-DeepCARS™ through its initial prospective research, has been published in "Critical Care," a leading international journal in intensive care medicine.

Key Points: 
  • VUNO announced that the multicenter clinical study paper, which confirms the clinical validity of VUNO Med®-DeepCARS™ through its initial prospective research, has been published in "Critical Care," a leading international journal in intensive care medicine.
  • In the study published in Critical Care, the VUNO research team conducted a multicenter study using patient data from general wards at four tertiary medical institutions: Seoul National University Hospital, Bundang Seoul National University Hospital, Inha University Hospital, and Dong-A University Hospital, each with varying sizes, locations, and medical environments.
  • The study found that the predictive performance of VUNO Med®-DeepCARS™ had an AUROC score of 0.869, outperforming traditional methods (NEWS 0.767, MEWS 0.756).
  • In this study, VUNO Med®-DeepCARS™ displayed exceptional predictive abilities and adaptability in identifying high-risk patients, even in its first prospective research.

ROKIT HEALTHCARE Achieves European Certification for Cutting-Edge Organ Regeneration

Retrieved on: 
Lundi, août 14, 2023
DFU, EEA, Immigration (European Economic Area) Regulations 2006, 3D bioprinting, European Economic Community, Foot, MFDS, SNUH, Certification, Regenerative medicine, Transplant, Ulcer, Korean Ministry of Culture, Publication, Seoul National University Hospital, Artificial intelligence, European Medical Students' Association, Health, FDA, Kidney disease, Gangneung Asan Hospital, Medical device, EU, Food

SEOUL, South Korea, Aug. 14, 2023 /PRNewswire/ -- ROKIT HEALTHCARE, a pioneering biotech firm specializing in advanced organ regeneration, proudly announces a significant milestone.

Key Points: 
  • SEOUL, South Korea, Aug. 14, 2023 /PRNewswire/ -- ROKIT HEALTHCARE, a pioneering biotech firm specializing in advanced organ regeneration, proudly announces a significant milestone.
  • In July 2023, the company obtained the coveted certification under the European Medical Device Regulation (CEMDR) for its revolutionary "Dr. Invivo AI Regen Platform."
  • The "Dr. Invivo AI Regen Platform" marks a leap in organ regeneration and medical device innovation, fusing artificial intelligence (AI) with bioprinting.
  • SeokHwan You, CEO of ROKIT HEALTHCARE, states, "This certification propels us globally, extending advanced medical solutions."